Retatrutide is called a triple agonist because a single molecule switches on three different hormone receptors: GIP, GLP-1 and glucagon. An agonist is anything that binds a receptor and activates it. Semaglutide works on one of these receptors, tirzepatide on two, and retatrutide, Eli Lilly’s experimental obesity drug, on all three.
What is an agonist?
Think of a receptor as a lock on the outside of a cell, cut to fit one hormone. The hormone is the key. When it turns, the cell responds, perhaps by releasing insulin.
An agonist is a key that turns. It can be the natural hormone or a lab-made copy. An antagonist works the other way, fitting the lock and jamming it so nothing else gets in. Semaglutide, tirzepatide and retatrutide are all agonists.
What do the three receptors do?
- GLP-1 is made in the gut wall. Its receptor, in the pancreas and the brain’s hunger centers, boosts insulin when blood sugar is high, slows stomach emptying and dampens appetite.
- GIP is a second gut hormone released after eating. Its receptor adds to the insulin response and appears to influence how the body handles fat.
- Glucagon comes from the pancreas and raises blood sugar between meals. In retatrutide, its signal appears to raise energy expenditure and push the liver to burn more fat.
Adding glucagon sounds backward. It pushes blood sugar up, after all. The design bets that the GIP and GLP-1 signals will hold glucose in check while glucagon adds its fat-burning effect on top.
From single to dual to triple agonists
The field moved one receptor at a time.
Natural GLP-1 is broken down by an enzyme called DPP-4 in about two minutes. Exenatide, a copy of a peptide found in Gila monster venom, resisted that enzyme and was approved for type 2 diabetes in 2005. Liraglutide, approved in 2010, added a fatty-acid chain that grips albumin in the blood, enough for once-daily dosing. Semaglutide stretched that to about a week.
Then came the multi-receptor drugs. Lilly introduced tirzepatide, coded LY3298176, as a dual GIP and GLP-1 agonist in a 2018 paper, and it was approved for type 2 diabetes in 2022 and for weight management in 2023. Retatrutide, coded LY3437943, arrived in a 2022 paper in Cell Metabolism as the triple.
| Type | Example | Receptors | Average weight loss in main obesity trial |
|---|---|---|---|
| Single agonist | Semaglutide | GLP-1 | 14.9% at 68 weeks (STEP 1) |
| Dual agonist | Tirzepatide | GIP, GLP-1 | 22.5% at 72 weeks (SURMOUNT-1) |
| Triple agonist | Retatrutide | GIP, GLP-1, glucagon | 28.3% at 80 weeks (TRIUMPH-1) |
Those figures come from separate trials, so they show a trend. The direct test is TRIUMPH-5, a head-to-head trial of retatrutide against tirzepatide in about 800 adults, which had not reported as of November 2026.
How does one molecule fit three receptors?
By compromise. Retatrutide is a chain of 39 amino acids built on the GIP hormone’s pattern, with a few unnatural building blocks swapped in to resist breakdown. In 2024, researchers in Shanghai used cryo-electron microscopy to see it bound to each receptor. The first 13 amino acids sink into the receptor’s core, the next 17 lie along its outer face, and the three receptor shapes differ by less than one angstrom.
The balance is uneven on purpose. Lab tests from the discovery work put retatrutide at 8.9 times the potency of natural GIP at the GIP receptor. At the GLP-1 and glucagon receptors it runs at roughly 0.4 and 0.3 of the natural hormones’ potency. A side-by-side of the two peptides shows how it compares with tirzepatide.
Where does retatrutide stand now?
Lilly reports five positive phase 3 trials and plans to file with the FDA in the first quarter of 2027. Until then, it’s investigational. Interest is running well ahead, with about 271,000 US Google searches a month, and sites such as WhereToBuyRetatrutide.org already compare the vendors selling it.
FAQs
What does triple agonist mean?
One drug activates three receptors. Retatrutide switches on the GIP, GLP-1 and glucagon receptors.
Is retatrutide stronger than tirzepatide?
In separate trials it has produced more weight loss. The first direct comparison, TRIUMPH-5, has not reported yet.
Sources
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 2018.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022.
- Li W, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery, 2024.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026.

